DC-DORSEY-&-WHITNEY-LLP
2.11.2020 18:26:12 CET | Business Wire | Press release
International law firm Dorsey & Whitney LLP announced today that former senior CFIUS official Justin Huff has joined the Firm as a Partner in its Washington D.C. office.
Before entering private practice, Mr. Huff served as a Deputy Director in the United States Department of the Treasury office responsible for chairing the Committee on Foreign Investment in the United States (CFIUS), an interagency committee that reviews cross-border mergers, acquisitions and certain investment transactions for potential national security concerns. Mr. Huff led the review of hundreds of CFIUS filings and conducted in-depth national security analyses on transactions across a wide range of industries, including biotech, agriculture, technology, telecommunication, real estate, energy, and others. Mr. Huff also engaged in extensive inter-agency communications and consensus building with the eight other agencies on the CFIUS committee.
Before his Treasury position, Mr. Huff served as a senior intelligence analyst for the Office of Homeland Security and Emergency Coordination at the U.S. Department of Agriculture, where he managed departmental requirements and briefed White House officials and other federal agencies. He also was a senior intelligence advisor at the Office of the Director of National Intelligence, where he worked across federal departments and agencies to rally interagency support for initiatives that enhanced intelligence and information sharing between federal departments and the intelligence community.
After serving in the federal government as a national security official for over a decade, Mr. Huff entered the private law practice at another international law firm. Mr. Huff guided domestic and international clients on CFIUS regulations and their impact on hundreds of high-profile cross-border corporate transactions. Clients praise Mr. Huff for his deep knowledge of the CFIUS regulations and process, and for his ability to find practical and business-sensitive solutions, whether for a pending transaction or in connection with a post-closing CFIUS investigation or review.
Mr. Huff joins an experienced team of Dorsey attorneys who have filed and handled CFIUS notices and investigations on behalf of domestic and international clients in cross-border M&A and investment transactions since 1988. The lawyers at Dorsey have appeared for various clients before CFIUS and, through that extensive experience, have developed excellent, close, and mutually respectful relationships with CFIUS management and staff, including, where appropriate, the ability to meet directly with those officials in Washington, DC.
“With his experience as a senior CFIUS officer, Justin is knowledgeable not only about CFIUS regulations but also about the internal CFIUS processes and practice,” said Dorsey managing partner Bill Stoeri. “In light of the significant changes in CFIUS regulations, including the adoption of the Foreign Investment Risk Review Modernization Act of 2018 (FIRRMA), the expansion of CFIUS jurisdiction, the mandatory filing requirements and expansion of CFIUS’s operations and enforcement, Justin’s expertise and experience will help Dorsey clients with the growing regulatory demands placed on cross-border transactions.”
About Dorsey & Whitney LLP
Clients have relied on Dorsey since 1912 as a valued business partner. With locations across the United States and in Canada, Europe and the Asia-Pacific region, Dorsey provides an integrated, proactive approach to its clients' legal and business needs. Dorsey represents a number of the world's most successful companies from a wide range of industries, including leaders in banking & financial institutions, development & infrastructure, energy & natural resources, food, beverage & agribusiness, healthcare and technology, as well as major non-profit and government entities. www.dorsey.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005791/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
